DexCom (NASDAQ:DXCM) Price Target Raised to $85.00 at JPMorgan Chase & Co.

DexCom (NASDAQ:DXCM) had its target price hoisted by JPMorgan Chase & Co. from $75.00 to $85.00 in a research note published on Friday, Benzinga reports. They currently have a neutral rating on the medical device company’s stock.

A number of other equities analysts have also recently weighed in on the company. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, October 12th. Barclays decreased their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Robert W. Baird boosted their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Royal Bank of Canada decreased their target price on shares of DexCom from $130.00 to $120.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Wells Fargo & Company increased their price target on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Price Performance

Shares of NASDAQ:DXCM traded down $1.41 during trading on Friday, hitting $73.44. 14,562,597 shares of the stock were exchanged, compared to its average volume of 3,904,948. The company has a market cap of $29.21 billion, a PE ratio of 47.38, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a fifty day moving average price of $70.11 and a two-hundred day moving average price of $98.24. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 24th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $994.20 million during the quarter, compared to the consensus estimate of $991.55 million. On average, analysts forecast that DexCom will post 1.69 EPS for the current year.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock worth $126,390 over the last ninety days. 0.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On DexCom

A number of large investors have recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the 2nd quarter valued at about $25,000. Sachetta LLC boosted its holdings in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC acquired a new stake in DexCom during the 1st quarter valued at approximately $29,000. Riverview Trust Co increased its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC raised its position in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.